SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.6387
-0.0213 (-3.23%)
At close: Nov 3, 2025, 4:00 PM EST
0.6644
+0.0257 (4.02%)
After-hours: Nov 3, 2025, 7:56 PM EST
SCYNEXIS Employees
SCYNEXIS had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change (1Y)
-1
Growth (1Y)
-3.45%
Revenue / Employee
$116,321
Profits / Employee
-$697,036
Market Cap
26.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2023 | 29 | -7 | -19.44% |
| Dec 31, 2022 | 36 | -20 | -35.71% |
| Dec 31, 2021 | 56 | 18 | 47.37% |
| Dec 31, 2020 | 38 | 11 | 40.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SCYX News
- 19 days ago - SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study - GlobeNewsWire
- 2 months ago - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) - GlobeNewsWire
- 2 months ago - SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - GlobeNewsWire
- 8 months ago - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 1 year ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - GlobeNewsWire